A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART(®)) protein in patients with relapsed/refractory metastatic colorectal carcinoma

Documenti analoghi

• EpCAM and gpA33 are markers of Barrett's metaplasia
  di: Wong, N A C S, et al.
  Pubblicazione: (2006)
• A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML)
  di: Uy, Geoffrey, et al.
  Pubblicazione: (2014)
• A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer
  di: Baughman, Jan, et al.
  Pubblicazione: (2015)
• The RNA backbone plays a crucial role in mediating the intrinsic stability of the GpU dinucleotide platform and the GpUpA/GpA miniduplex
  di: Lu, Xiang-Jun, et al.
  Pubblicazione: (2010)
• Target identification using drug affinity responsive target stability (DARTS)
  di: Lomenick, Brett, et al.
  Pubblicazione: (2009)